Physician profile
Gary K Berman
NPI 1609981281
$6,813.53
in general payments reported to CMS, 2019-2025
13 companies · $198 in 2025
The $198 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,678 · 2020: $11.86 · 2021: $1,441 · 2022: $35.00 · 2023: $38.62 · 2024: $411 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $584 · Entertainment: $64.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $583.87 |
| Entertainment | $64.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $4,639.59 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $1,300.00 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $280.27 | 2024-2025 | Jardiance |
| Boston Scientific Corporation | $158.53 | 2019-2024 | |
| Novo Nordisk INC | $140.67 | 2023-2025 | Ozempic |
| Janssen Pharmaceuticals, INC | $123.73 | 2021 | |
| Stereotaxis INC | $64.13 | 2025 | Genesis |
| Pfizer INC. | $25.16 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $21.70 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.06 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $15.99 | 2023 | Farxiga |
| Amarin Pharma, INC. | $14.44 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $12.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Berman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.